my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
22-06-2012: Raptor Pharmaceutical Corp. announced that the Company has acquired exclusive rights to intellectual property related to cysteamine and related compounds in the potential treatment of Parkinson's Disease from Université Laval.
Raptor's agreement with Laval provides exclusive rights to technology related to the use of cysteamine and related compounds to potentially modify the progression of Parkinson's Disease. Researchers at Laval reported that administration of cystamine (an oxidized form of cysteamine) in an animal model of Parkinson's Disease showed signs of preventing neuron loss and rescuing neurons undergoing a degenerative process. Signs of restoration and partial reversal of behavioral impairments were also observed.
Dr. Patrice P. Rioux, Raptor's Chief Medical Officer, stated, "The agreement with Laval extends our existing portfolio in neurodegenerative diseases. We are currently conducting a Phase 2/3 clinical trial in France of Delayed-release Cysteamine Bitartrate capsules (RP103), for the potential treatment of Huntington's Disease. The researchers at Laval have compiled a solid preclinical foundation which, when combined with the existing safety profile of cysteamine, may enable us to more rapidly advance this program for the potential treatment of Parkinson's Disease in to a Phase 2 clinical trial. We plan to seek grant support to help fund the clinical development of RP103 in Parkinson's, as we have done with our Huntington's and NASH programs."
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Raptor Pharmaceutical Corp. Expands Senior Management
Raptor Pharmaceutical Corp. announced the appointment of Georgia Erbez, as Chief Financial Officer of Raptor, and Julie Anne Smith, as Executive Vice President, Strategy, and Chief Operating Officer. Ms. Erbez will be responsible for directing Raptor's global financial strategy and organiza ... more
Raptor Pharmaceutical Corp. announced that the Company has acquired exclusive rights to intellectual property related to cysteamine and related compounds in the potential treatment of Parkinson's Disease from Université Laval.Raptor's agreement with Laval provides exclusive rights to techno ... more
Raptor Pharmaceutical Corp. announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) part of the National Institutes of Health (NIH) to conduct a Phase 2b clinical trial. The clinical ... more
Raptor Pharmaceutical Corp. announced that the Company has acquired exclusive rights to intellectual property related to cysteamine and related compounds in the potential treatment of Parkinson's Disease from Université Laval.Raptor's agreement with Laval provides exclusive rights to techno ... more
Plastic biochip speeds up protein detection
A new, fast, and inexpensive way to test for medically important molecules, such the blood clot protein thrombin and faulty proteins present in Alzheimer's disease, could emerge from research published in the journal Advanced Materials. Mario Leclerc and his colleagues at Université Laval i ... more
Located in Quebec City, Université Laval is the first French-language university in North America. It is one of Canada's leading universities, ranking 7th among the country's 95 university-level institutions in terms of research funding, with more than $300 million devoted to research last ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
